Ulcers in the stomach, duodenum, ileum/jejunum and colon may look alike grossly and microscopically, but they have very
different etiologies and pathogenesis. Unfortunately, there is virtually no etiologic treatment for any of these lesions which are also accompanied
by limited or extensive inflammation. This article reviews four groups of new antiulcer drugs discovered and patented in our
lab in Boston and Long Beach/Irvine (Table 1). Actually, the first group, pyrazole and its derivatives can be used for prevention, i.e., long
lasting protection of gastric mucosa against alcohol- or NSAID-induced erosions. Dopamine seems to be a new etiologic treatment for
both upper and lower GI tract ulcers. Angiogenic growth factors like bFGF or PDGF (daily administration as peptides orally or by rectal
enemas, or as single or double-dose of gene therapy) accelerated the healing of gastroduodenal ulcers and UC, while VEGF seems to be
effective only for upper GI tract ulcers. Last but not least, a novel group of angiogenic steroids which not only stimulate new blood vessel
formation and granulation tissue production (essential elements of healing of ulcer types) but may also exert mild or prominent antiinflammatory
action and seem to be ideal drugs for the treatment of IBD.
Keywords: Angiostatic steroids, angiogenic steroids, angiosteroids, angiogenic growth factors, bFGF, Crohn’s disease, dopamine, gastric and
duodenal ulcers, inflammatory bowel diseases, PDGF, pyrazole derivatives, ulcerative colitis, VEGF.
Rights & PermissionsPrintExport